Recombinant Human Thrombomodulin (C-6His)

Description

EnkiLife provides the Recombinant Human Thrombomodulin (C-6His) protein,aslo know as Thrombomodulin,THBD,TM,Fetomodulin,CD141,THRM, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Thrombomodulin is produced by our Mammalian expression system and the target gene encoding Ala19-Ser515 is expressed with a 6His tag at the C-terminus.Accession:P07204. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:52.9 KDa. Background:Thrombomodulin is a specific endothelial cell receptor that forms a 1:1 stoichiometric complex with thrombin. This complex is responsible for the conversion of protein C to the activated protein C (protein Ca). Human Thrombomodulin/THBD predicts a signal peptide and a mature chain that consists of following domains: C-type lectin, EGF-like, transmembrane and cytoplasmic. Predominantly synthesized by vascular endothelial cells, THBD inhibits coagulation and fibrinolysis. THBD gene polymorphisims are associated with human disease and THBD plays a role in thrombosis, stroke, arteriosclerosis, and cancer. For example, increased serum levels of THBD, due to protease cleavage, have been associated with smoking, cardiac surgery, atherosclerosis, liver cirrhosis, diabetes mellitus, cerebral and myocardial infarction, and multiple sclerosis.